Multiple Myeloma | Norton Healthcare

Indication: Multiple Myeloma

Open-label, Multicenter, Non-randomized Phase 2 Study OF PF-06863135 Monotherapy in PARTICIPANTS WITH Multiple Myeloma WHO ARE REFRACTORY TO At LEAST One PROTEASOME Inhibitor, ONE immunomodulatory drug and ONE anti-cd38
antibody

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Pfizer

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.